Key Takeaways Amicus' Galafold recorded $233.1M in H1 2025 sales, up 11% year over year.Label expansion and global approvals have boosted Galafold's revenue growth in recent times.Teva settlement blocks Galafold generics in the United States until January 2037.Amicus Therapeutics’ (FOLD) lead product, Galafold (migalastat), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.Galafold is the first oral precision medicine approved for treating patien ...